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Xenograft models are invaluable tools in establishing the currentparadigms of hematopoiesis and leukemogenesis. The zebrafishhas emerged as a robust alternative xenograft model but, like
mice, lacks specific cytokines that mimic the microenvironment found in
human patients. To address this critical gap, we generated the first
“humanized” zebrafish that expresses human hematopoietic-specific
cytokines (granulocyte-monocyte colony-stimulating factor, stem cell
factor, and stromal cell-derived factor 1α). Termed GSS fish, these
zebrafish promote survival, self-renewal and multilineage differentiation
of human hematopoietic stem and progenitor cells and result in
enhanced proliferation and hematopoietic niche-specific homing of pri-
mary human leukemia cells. Using error-corrected RNA sequencing, we
determined that patient-derived leukemias transplanted into GSS
zebrafish exhibit broader clonal representation compared to transplants
into control hosts. GSS zebrafish incorporating error-corrected RNA
sequencing establish a new standard for zebrafish xenotransplantation
which more accurately recapitulates the human context, providing a
more representative cost-effective preclinical model system for evaluat-
ing personalized response-based treatment in leukemia and therapies to
expand human hematopoietic stem and progenitor cells in the transplant
setting.
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The availability of xenograft models has dramatically influenced our current under-
standing of leukemogenesis and stem cell biology over the last decade. Patient-
derived xenografts provide a better microenvironmental and stromal context than any
in vitro system because they maintain the clonal heterogeneity inherent in human can-
cers, which is of translational importance for assays that involve pharmacological
interventions and responses.1,2 Current gold standard xenograft assays use small mam-
mals, like the mouse, with a depleted immune system in models that have been
refined over many years from their original derivation.3-6 However, findings from
these murine xenografts may not be congruent with similar experimental results
observed in human studies.7 Some human samples do not engraft in a foreign host,
while in other cases, following successful initial engraft-
ment, the chimera disappears over time. Given that
xenografts include both human tumor and host stroma
(including immune cells), these discrepancies are accounted
for, in part, by the lack of evolutionary conservation of
microenvironmental signaling pathways between humans
and rodents.
Further, cytokines present in the microenvironment are
essential for the differentiation and maintenance of individ-
ual cells but are not entirely conserved across species.8 For
example, there is a lack of conservation of interleukin 3 (IL-
3) and granulocyte-macrophage colony stimulating factor
(GM-CSF/CSF2) between humans and mice at the amino
acid level, evidenced by the fact that mouse IL-3 and GM-
CSF do not react with their respective human receptors.9,10
Thus, to compensate for these limitations, efforts to
“humanize” rodent model systems have led to the introduc-
tion of human microenvironmental factors along with
human cell populations.11,12
Various efforts have been made to introduce human fac-
tors into model organisms, including the injection of recom-
binant proteins such as PIXY321 (a GM-CSF/IL-3 fusion
protein)4 and a cost-efficient method to enable human
cytokine expression using knock-in10,13 and transgenic tech-
nologies,11,14 where researchers have introduced various fac-
tors including erythropoietin and IL-3. The approach of
humanizing mice has been successful to the extent that it
permits enhanced engraftment and, depending on the
cytokine introduced, differentiation and maintenance of
specific cell lineages. For example, humanized transgenic
SGM3 mice expressing human stem cell factor/KIT ligand
(SCF/KITLG), GM-CSF and IL-3 showed a significant
increase in the myeloid15 and mast cell compartments16 and
improved engraftment efficiency of human acute myeloid
leukemia (AML) cells.11 This modified murine xenograft
model provides a unique advantage to enhance clonal het-
erogeneity and thereby enrich for more robust and mean-
ingful responses to pharmacological interventions.
However, the mouse model has significant limitations: it
remains laborious, is limited to small numbers of animals,
and human cells take months to engraft. As such, they are
not amenable to high- or medium-throughput drug screen-
ing efforts and cannot provide results to inform patient
management decisions in a clinically actionable time-frame. 
We previously pioneered a zebrafish larval xenograft
assay to study human leukemia progression and demon-
strated the feasibility of employing this platform for pri-
mary patient bone marrow-derived T-cell acute lym-
phoblastic leukemia (T-ALL) samples.17-19 The zebrafish
xenograft platform offers several advantages, including a
high degree of genetic conservation with humans at the
protein level20 with the added benefit of visual tractability of
human cells in an organism amenable to medium-through-
put chemical screening.21,22 However, similar to mice,
zebrafish express evolutionarily divergent cytokines (or
lack them altogether) that are critical to the maintenance of
human cell clonal heterogeneity. Previous publications have
suggested that the receptors and ligands of the IL-3 subfam-
ily that include IL-5, GM-CSF, and IL-3 are absent in
zebrafish,23 and in silico analysis revealed that the critical cell
migration chemokine, CXCL12/SDF1α, is conserved less
than 50% at the amino acid level between humans and
zebrafish. 
While zebrafish leukemia xenograft platforms have been
successful,17,18 the survival of human hematopoietic stem
and progenitor cells (HSPC) in zebrafish is uncertain. It was
previously demonstrated that HSPC do not survive in
zebrafish for more than 12 hours,24 while a recent study
showed that they could survive only up to 13 hours post-
injection,25 raising concerns whether the zebrafish host
enable human HSPC survival and clonal expansion after
transplantation. As such, zebrafish xenograft approaches to
date share a flaw in lacking an optimal microenvironment
to support the clonal evolution of human HSPC and
leukemia cells, questioning the clinical transferability of
findings from this model. To address this critical gap, we
have generated a humanized zebrafish that expresses mul-
tiple human hematopoietic-specific cytokines. We subse-
quently transplanted primary human-derived HSPC and
leukemia cells and performed clonal heterogeneity evalua-
tion using error-corrected sequencing (ECS). Using these
humanized zebrafish models, we reveal that transgenic fish
expressing human cytokines prolong survival and differen-
tiation of human HSPC. Furthermore, in the presence of
these critical cytokines, transplanted leukemia cells exhibit
hematopoietic niche homing that more accurately models
the behavior of human leukemia. These results lay the
foundation for a new paradigm in zebrafish xenograft-
based drug discovery platforms for molecular targeting of
human leukemia and the expansion of HSPC.
Methods
Zebrafish studies
All zebrafish studies reported were approved by the Dalhousie
University Committee on Laboratory Animals (UCLA), under pro-
tocol #17-007. Briefly, the tol2 constructs were injected into single-
cell stage zebrafish to make the human CXCL12/SDF1α and the
human SCF/KITLG and GM-CSF/CSF2-expressing transgenic
zebrafish. Fish were further crossed to make a humanized triple
GSS (GM-CSF, SCF, and SDF1α) transgenic fish (see details in the
Online Supplementary Methods). The casper26 strain of double pig-
ment zebrafish mutants was used to generate all transgenic and
control fish. 
Human umbilical cord and bone marrow samples
The use of human samples in the study was approved by the
IWK Health Center Research Ethics Board (REB# 1007549 & REB#
1007549). Fresh human umbilical cord blood and human leukemia
bone marrow samples were collected from patients at IWK Health
Center (Halifax, Nova Scotia, Canada) after formal consent had
been obtained. For leukemia samples, the buffy coat was isolated,
and the white blood cells were cryopreserved directly. For samples
from umbilical cord blood, post-buffy coat isolation, the samples
underwent immunomagnetic enrichment to isolate lineage-deplet-
ed (lin-)HSPC. 
Orthotropic xenograft experiments with primary 
samples
Both transgenic and control (casper) larvae were treated with 10
mg/mL doxycycline hydrochloride (Sigma Aldrich) at 24 hours
post-fertilization (hpf) to induce the expression of SCF/KITLG and
GM-CSF/CSF2 in transgenic fish and as a control for any drug
effects in casper larvae. All larvae were irradiated at 72 hpf to
induce cxcl12 promoter activity and niche clearance of the organ-
ism for transplant. Human patient-derived samples were then
labeled with a cytoplasmic green fluorescent dye to facilitate in vivo
cell tracking, and approximately 150-250 cells were injected into
the common cardinal vein. The larvae were screened immediately
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following the injection to confirm that cells were present in the cir-
culation and then moved to a 35°C incubator, a previously-estab-
lished compromise between the normal developing temperature
of zebrafish (28.5°C) and human cells (37°C).18,27 Detailed methods
are provided in the Online Supplementary Methods.
Results
Generating “humanized” transgenic zebrafish
To improve the current zebrafish platform for human
leukemia and HSPC xenografts, we generated transgenic
zebrafish expressing human hematopoietic cytokines.
Cytokines that are poorly conserved between human and
zebrafish but that have been demonstrated to be critical for
normal hematopoiesis were chosen for this study. In this
regard, the CXCR4 ligand, CXCL12/SDF1α, was our prior-
ity, given its functions in stem cell fate decisions such as
expansion, homing, self-renewal, differentiation, control of
stem cell exhaustion and protection against genotoxic
stress.28-30 Both GM-CSF/CSF2 and SCF/KITLG were also
determined to be essential candidates based on previous
mouse experiments.11 Due to its redundant function with
CXCL12 and GM-CSF/CSF2, we did not incorporate IL-3,
which was previously used in mouse models. We devel-
oped two independent transgenic zebrafish models by co-
injecting tol2 mRNA and plasmids (Figure 1A, C). One
expresses human CXCL12 under the zebrafish cxcl12 pro-
moter (Figure 1B) while the other expresses human KITLG
and CSF2 under a tetracycline-inducible promoter (Figure
1D); expression was confirmed using immunoblotting
(Figure 1E).
Humanized zebrafish demonstrate enhanced human
leukemia cell migration and proliferation
We initially performed validation experiments in the
CXCL12 and GM-CSF/CSF2-SCF/KITLG compound trans-
genic models separately. The CXCR4-CXCL12 axis is criti-
cal for cell migration and homing.31 We therefore selected
migration as a mode of validation for the human CXCL12-
expressing transgenic zebrafish. Jurkat cells are a human T-
ALL cell line that expresses high levels of CXCR4, the cog-
nate CXCL12 receptor.32 Zebrafish cxcl12 promoter expres-
sion begins only at 72 hpf, so we injected Jurkat cells into
the yolk sac of CXCL12-expressing and casper control larvae
at 72 hpf and screened for migration at 3 days post-injection
Humanized fish enhance AML and HSPC engraftment.
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Figure 1. Humanized transgenic zebrafish express human CXCL12, KITLG, and CSF2. Transgenic zebrafish expressing human cytokines were generated by co-inject-
ing tol2 mRNA and plasmids (A and C). (A) A cartoon of the construct used to make the transgenic zebrafish expressing human CXCL12 (hCXCL12) along with tagBFP
under the zebrafish cxcl12 promoter. (B) Representative image of a transgenic zebrafish expressing human CXCL12 in the posterior hemal arc near the tip of the tail
at 3 days post-fertilization (dpf). CXCL12 expression continues to progress anteriorly through the hemal arc (representative image shows 8 dpf larvae). (C) A cartoon
of the constructs used to make the tet-inducible human SCF/KITLG and GM-CSF/CSF2 expressing zebrafish. (D) Representative image of the human SCF/KITLG
(hKITLG) and GM-CSF/CSF2 (hCSF2)-expressing zebrafish. Image specification: magnification = 5x, numerical aperture = 0.16. (E) Representative western blot show-
ing expression of human GM-CSF/CSF2 (hCSF2) and SCF/KITLG (hKITLG) in transgenic zebrafish. S1 and S2 denote samples from the transgenic larvae, and C1 and






(dpi). We categorized each injected fish into one of the fol-
lowing categories: "no migration," "local dissemination,"
(dissemination within the yolk sac), and "migration" (dis-
tant migration beyond the yolk sac). There was no migra-
tory difference between the cells injected into control versus
CXCL12 fish (top panels, Figure 2A, B). However, expres-
sion of CXCL12 is low at this time point and is restricted to
the posterior hemal arc near the tail. Previous studies have
shown that DNA double-stranded breaks caused by either
gamma irradiation or chemical agents, such as 5-fluo-
rouracil or etoposide, can cause an increase in CXCL12
expression.33,34 Thus, we gamma-irradiated zebrafish larvae
with a sublethal dose of radiation (15 Gy) 2 hours before
transplantation and repeated the assay. We observed a dras-
tic increase in the number of CXCL12 larvae that exhibited
human T-ALL cell migration compared to the controls (bot-
tom panels, Figure 2A, B). From the cells that migrated out
of the yolk sac, we also saw hematopoietic niche-specific
homing to the caudal hematopoietic tissue (CHT) at 144
hpf and later to the kidney marrow at 216 hpf (Online
Supplementary Figure S1).
For the transgenic fish expressing GM-CSF/CSF2 and
SCF/KITLG (GS fish), we used CMK, a human Down syn-
drome acute myeloid leukemia (ML-DS) cell line for valida-
tion. While CMK cells survive in culture without additional
cytokines, previous experiments in our hands demonstrat-
ed drastic cell death in zebrafish xenograft assays, suggest-
ing that the cells are susceptible to their microenvironment.
It was recently demonstrated that GM-CSF/CSF2 enhances
survival in Down syndrome transient abnormal
myelopoiesis (TAM), suggesting a growth advantage for
ML-DS under GM-CSF/CSF2-rich conditions.35 When CMK
cells were injected into GS larvae, xenografts demonstrated
increased cell proliferation at 3 dpi compared to casper con-
trols (Figure 2C, D). Strikingly, this was preceded by a sud-
den decrease in the number of CMK cells in both control
and transgenic larvae at 2 dpi (Figure 2D). These cells were
injected into the yolk sac, an acellular environment, which
may have resulted in delayed proliferation due to the
restricted access of injected cells to circulating human
cytokines. Thus, moving forward, all xenografts were per-
formed by injection directly into the bloodstream of larval
zebrafish, which is likely more relevant to adult human
hematopoiesis.  This strategy is in keeping with a recent
emphasis on mechanochemical mechanisms, such as blood
flow, leading to blood stem cell regulation.36
Humanized zebrafish larvae show improved response 
to drug administration compared to controls
Following our previous observation, we evaluated
whether xenotransplantation of human cells into the circu-
lation of GSS fish improved proliferation compared to that
following yolk-sac injection. We injected human ML-DS
CMK cells into both the yolk sac and the circulation of the
larvae and observed a trend to increased proliferation of
cells injected into the circulation compared to that of cells
injected into the yolk sac (Online Supplementary Figure S2A).
We then wanted to evaluate the fitness of our model in a
preclinical drug-testing scenario. The ML-DS CMK cells
were established from a 10-year old patient who responded
to cytarabine. We wanted to determine whether this
response was conserved in the context of GSS larvae. We
injected CMK cells into the circulation of both GSS and
casper larvae. The larvae were divided into two groups, and
one group was treated with 1 mM cytarabine 1 day-post
injection. While there was no significant difference
between the cytarabine administered and untreated casper
groups (P=0.94), the GSS larvae treated with cytarabine did
show a significant decrease in the number of cells com-
pared to the untreated control (P=0.005) (Online
Supplementary Figure S2B).
GSS transgenic larvae show increased mortality 
compared to controls when transplanted with primary
acute myeloid leukemia cells 
Following these validation experiments, both transgenic
zebrafish lines were crossed to create a GSS (GM-
CSF/CSF2, SCF/KITLG and SDF1α/CXCL12) triple trans-
genic fish. We wanted to compare engraftment and expan-
sion of primary patient-derived leukemias in the GSS larvae
to controls. These xenografts were performed orthotopical-
ly by injecting primary AML cells into the circulation (com-
mon cardinal vein) at 72 hpf. We xenografted four distinct
pediatric patient-derived AML samples: a CBL exon 8 dele-
tion with KMT2A-MLLT3 (MLL-AF9) fusion by karyotype
(A23352); KRAS G12C point mutation (A23280), KMT2A-
MLLT3 fusion (AS12029811) and a ML-DS sample.
Immediately post-injection, larvae were screened to select
for a similar number of cells in both GSS and control groups
of fish. We tracked the larvae until one of the groups
reached 50% mortality and used the remaining larvae for
targeted ECS) (Figure 3A). While the number of days
required to reach 50% mortality varied across AML sam-
ples, the GSS fish consistently suffered greater mortality
compared to control larvae (Figure 3A). This indicates
increased cellular proliferation and leukemic burden,
because when transplanted with human HSPC, both con-
trol and GSS larvae showed almost negligible death (Online
Supplementary Figure S3). Since most leukemias are hetero-
geneous, they provide us with polymorphism or mutation-
specific biomarkers that enable screening for clonal conser-
vation. We prepared RNA from human AML xenografted
control and GSS zebrafish and performed RNA-ECS to
quantify clonal variability and conservation via the relative
abundance of human leukemia-specific gene transcripts in
the background of zebrafish transcripts. While some single
nucleotide polymorphism variants were detected alterna-
tively in the GSS or the control fish, overall the GSS fish
retained a higher number of single nucleotide polymor-
phism variants representing more leukemic clones than the
control fish. Mutations such as NOTCH (5094 C>T) and
ALK (3375 C>A), which are silent and hence not pathogen-
ic, were only present with a high allelic frequency (>0.5) in
GSS xenografts, suggesting the elimination of some clones
in the controls (Figure 3B). Altogether, the data from both
the control and GSS xenografts yielded 46 high confidence
nucleotide variants, of which only 23 (50%) were repre-
sented in controls compared to 42 (93.4%) variants repre-
sented in the GSS zebrafish. This finding demonstrates that
the GSS zebrafish provides a superior microenvironment
for survival and expansion of human AML clonal diversity. 
The CXCR4-CXCL12 locus is dispensable for 
the migration of human leukemia cells to the caudal
hematopoietic tissue but necessary for homing 
to the kidney marrow
During validation of the CXCL12 transgenic zebrafish,
we injected Jurkat cells into the yolk sac of 3 dpf larvae, and
a proportion of the cells transplanted into the transgenic lar-
vae showed migration to the CHT, a region equivalent to
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the fetal liver in humans. However, when we performed
primary AML xenografts and injected these cells into the
circulation, cells migrated to CHT uniformly in both control
and transgenic larvae. Since the kidney marrow (KM), the
zebrafish equivalent of human bone marrow, plays the role
of the hematopoietic niche after migration from the CHT,
we were curious to determine whether there was any dif-
ference in the migratory behavior to the KM between the
GSS and casper larvae. We observed a profound difference
in KM homing, with primary AML samples injected into
the GSS larvae showing a propensity to migrate to the KM,
which was not seen in controls (Figure 3C). In CXCL12
knock-out mouse models, hematopoietic stem cells migrat-
ed from the aorta-gonad-mesonephros to the fetal liver, but
fetal liver to bone marrow homing was impaired.37,38
However, previous in vitro studies showed that hematopoi-
etic stem cells from both fetal liver and bone marrow could
respond to CXCL12 stimuli in a Boyden chamber assay.39
Together, these findings highlight that while the CXCR4-
CXCL12 axis is critical in bone marrow homing, it may be
dispensable for fetal liver homing. We wanted to see if the
homing of human leukemia cells to the zebrafish CHT was
dependent on CXCL12-CXCR4. To do this, we returned to
T-ALL, in which we had initially seen differential homing
Humanized fish enhance AML and HSPC engraftment.
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Figure 2. Irradiation of human CXCL12-expressing transgenic zebrafish dramatically increases cell migration, while myeloid leukemia cells exhibit enhanced prolif-
eration in the presence of CSF2/GM-CSF and KITLG/SCF. (A) Human Jurkat cells  (which highly express CXCR4, the receptor for CXCL12) were xenografted into control
casper and CXCL12-expressing larvae, which were further divided into two groups: one which received 15 Gy irradiation and the other no irradiation at 72 hours post-
fertilization (hpf). Larvae were screened for cell migration at 144 hpf. Representative images of control and CXCL12-expressing larvae that were not irradiated uooer
panel). Representative images of control and CXCL12-expressing larvae following 15 Gy gamma irradiation (lower panel). (B) Quantification of cell migration was clas-
sified into “no migration,” “local dissemination” (dissemination within the yolk sac) and “migration” (distant migration beyond the yolk sac). Results represent three
independent experiments. Numbers on the bar denote the total number of larvae per classification. (C) Representative images of zebrafish injected with CMK cells,
a myeloid leukemia of Down syndrome (ML-DS) cell line. (D) Cell proliferation was quantified in transgenic larvae expressing GM-CSF/CSF2 and SCF/KITLG (GS fish)
and casper controls following enzymatic digestion and dissociation at 1 day post-injection (dpi) (baseline), 2 dpi and 3 dpi. The analysis included fluorescence
microscopy and cell counting. At 2 dpi there was a slight decrease in cell numbers in both transgenic and control larvae. By 3 dpi there was an increase in cell numbers
in GS larvae, whereas cell numbers in control larvae decreased. Data presented represents four replicates with each dot in the bar graph denoting a single replicate.
SCF/KITLG: stem cell factor/KIT ligand; GM-CSF/CSF2: granulocyte-monocyte colony-stimulating factor/colony-stimulating factor 2.
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using Jurkat cells, and this time employed a primary
patient-derived T-ALL sample expressing very high levels of
CXCR4. This sample was injected into the circulation of
GSS and control larvae. The majority of the T-ALL cells in
both control and GSS transgenic larvae migrated and sta-
tioned in the CHT, consistent with publications from other
groups.40,41 However, in contrast to other zebrafish
reports,40,41 following the addition of either a CXCR4-target-
ing antibody or isotype control, transplanted human T-ALL
cells continued to migrate to the CHT (Online Supplementary
Figure S4). These data are consistent with murine data and
suggest that the CXCR4-CXCL12 axis does not contribute
significantly to the migration of cells to the fetal liver.
Xenotransplanted of human hematopoietic stem cells
and progenitor cells in GSS fish exhibit both enhanced
self-renewal capacity and multilineage differentiation
Despite the widespread success of human tumor engraft-
ment in zebrafish, normal tissue xenografts, including
hematopoietic cells, have not been reported to engraft suc-
cessfully.24 Given the enhanced proliferation observed for
human leukemia samples transplanted into the GSS
zebrafish, we wanted to determine if the presence of
human cytokines could enhance human HSPC survival and
differentiation in a zebrafish host. We collected umbilical
cord blood from newly delivered infants and isolated line-
age-depleted (lin-) cells, which are highly enriched for
human HSPC. These cells were fluorescently labeled with a
cytoplasmic dye and transplanted into the circulation of
both casper control and GSS larvae at 72 hpf. Consistent
with previous reports, human HSPC did not survive past 24
hours in control larvae,24 but HSPC transplanted into GSS
larvae continued to survive past 48 hours after which the
cells began losing the cytoplasmic dye (Figure 4A). We
extracted RNA for targeted exon sequencing from both
control and GSS-injected larvae between 20-24 hpi. Of the
three samples sequenced, only one sample injected into the
casper larva had a detectable level of the human transcripts,
in contrast to the GSS larvae, for which all three HSPC
xenografted samples were found to have detectable human
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Figure 3. Patient-derived acute myeloid leukemia transplantation into GSS transgenic larvae increases leukemia-related disease mortality and shows increased
clonal representation in comparison to control larvae. (A) Kaplan-Meier curve showing increased acute myeloid leukemia (AML)-related mortality in GSS larvae
transplanted with each of four different patient-derived AML samples compared with casper control larvae transplanted with the same samples (P<0.0001). (B)
Heatmap showing increased clonal representation in the GSS larvae compared to control larvae transplanted with the same sample as measured by RNA-error cor-
rected sequencing. Different colors represent allele frequency from 0.002 (dark blue) to 1 (yellow). The white box represents an absence or allele frequency of less
than 0.002. (C) Representative immunofluorescence images from sagittal zebrafish sections showing human CD33+ AML cells localized in the kidney marrow of the
GSS transgenic fish. The left panel shows an overview of the fish section at 10x, and the white box highlights the region of interest. The top three right panels show
images taken under normal exposure based on controls and the overexposed image shown in the middle of the lower three panels illustrates the kidney morphology.
The parameters were kept constant between GSS and control sections during imaging (N=5). The yellow scale bar is equivalent to 100 mm, and the red scale bar is
equivalent to 10 mm. The top panel shows images from kidney marrow of control larvae injected with human AML samples, where leukemia cells are not present,
and the bottom shows GSS larvae with human CD33+ AML cells. Image specifications: 10x images: numerical aperture (NA) = 0.45; 63x images: NA = 1.4, Zoom =
1.5. GM-CSF/CSF: granulocyte-monocyte colony-stimulating factor/colony-stimulating factor; SCF/KITLG: stem cell factor/KIT ligand; CXCL12/ SDF1α:CXCL12/stro-




transcripts present. To further determine if human tran-
scripts were genuinely absent in the control fish, we per-
formed another round of ECS-RNA library preparation and
increased the starting total RNA from 100 ng to 300-500 ng
(depending on RNA availability). The absence of a
detectable level of human transcripts was confirmed. Upon
targeted transcriptome sequencing, we found that multilin-
eage differentiation occurred in both GSS and control lar-
vae, but with a myeloid bias. In the lymphoid lineage, only
B cells were sufficiently tractable, and transcripts of early T-
cell markers, CD3E and PTCRA, were absent, suggesting an
absence of T-cell differentiation (Figure 4B). In terms of self-
renewal capacity, HSPC transplanted into GSS larvae
showed increased expression of both CD34 and GATA2
(Figure 4B). Specifically, there were 194 and 4,682 error-cor-
rected transcripts of the human CD34 gene in 100 ng total
RNA input for control and GSS samples, respectively. While
CD34 is a bona fide HSPC marker in hematopoietic cells,
GATA2 is required for the maintenance, generation, and
survival of HSPC.42 The increased expression of CD34 and
GATA2 suggests that HSPC undergo self-renewal only in
the cytokine-rich context found in GSS larvae, but not in
controls. 
Discussion
While murine xenografts have provided essential insights
into human leukemia pathogenesis,3,4,11 and despite even
more excellent opportunities provided by ever more
immunocompromised hosts, this model system continues
to have limitations. Primary leukemia xenografts remain
challenging in mice for many reasons, including intrinsic
leukemic properties, absence or lack of bioactivity of some
of the human factors found in the host microenvironment,
and the presence of innate immune cells in the organism
Humanized fish enhance AML and HSPC engraftment.
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Figure 4. Umbilical cord blood-derived hematopoietic stem and progenitor cells show engraftment, self-renewal and multilineage differentiation in GSS larvae. (A)
Representative image of GSS larvae and casper control larvae transplanted with umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPC).
Image shows near complete absence of HSPC in control larvae at 28 hours post-injection (hpi), whereas the HSPC continue to survive in the GSS larvae at 28 hpi
and HSPC are seen until 72 hpi (N=20/genotype). Image specification: magnification =10x, numerical aperture = 0.3. White and black scale bars represent 100
µm and the yellow scale bar represents 50 mm. (B) Heatmap from RNA sequencing analysis of transplanted HSPC shows the increased expression level of self-renew-
al specific genes in HSPC transplanted into GSS larvae. Control and GSS larvae showed an identical expression of different lineage-specific genes. GM-CSF/CSF:
granulocyte-monocyte colony-stimulating factor/colony-stimulating factor; SCF/KITLG: stem cell factor/KIT ligand; CXCL12/ SDF1α:CXCL12/stromal cell derived fac-
tor 1α; GSS: GM-CSF/CSF, SCF/KITLG, CXCL12/SDF1α−expressing transgenic zebrafish.
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that eliminate transplanted cells. Moreover, the complexity
of these murine xenograft experiments, including the time
to engraftment (typically 3-6 weeks), renders studies chal-
lenging to conduct in a high-throughput setting, and thus
not readily amenable to clinically actionable drug screening
experiments. Our group has pioneered human leukemia
xenografts in zebrafish larvae and shown that this approach
is amenable to medium-throughput drug screening in an
actionable time-frame of 1-2 weeks.17,18 However, the issue
of conserved elements within the tumor microenvironment
is also applicable, as illustrated by previous unsuccessful
efforts to develop sustainable human HSPC zebrafish
xenografts.24
To address the inherent limitations of the zebrafish
microenvironment for sustaining human tumor xenografts,
we created a humanized zebrafish model, the GSS fish,
which expresses human CXCL12/SDF1α, SCF/KITLG, and
GM-CSF/CSF2 to enhance human HSPC and patient-
derived leukemia engraftment to enable real-time preclini-
cal therapeutic studies. As prior humanized mouse models
informed our choice of cytokines, the GSS fish resembles
the NSG-SGM3 mouse model,11,43 which expresses three
cytokines with poor conservation between mouse and
humans: GM-CSF, SCF, and IL-3. Zebrafish, being more
evolutionarily distant, have only 20% conservation with
the human CXCL12 ligand (Online Supplementary Figure
S5A, B) and considerable alteration in the CXCR4 binding
region in humans (Online Supplementary Figure S5C). IL-3 is
a critical factor in the expansion and chemotaxis of
hematopoietic cells, but hematopoietic cytokines often per-
form redundant functions. For its expansion and homing
function, IL-3 activates Raf/MEK/ERK signaling and small
GTPases such as Rac and Ras. CXCL12 follows a very sim-
ilar mechanism of action and additionally controls the fate
of hematopoietic stem cells by restricting differentiation
and enhancing stemness.44 GM-CSF, IL-3, and IL-5 also
share a common β chain that acts as a signaling subunit.45
GM-CSF also redundantly activates STAT and JAK2 path-
ways such as IL-3.46 So, we hypothesized that together SCF,
GM-CSF, and CXCL12 would compensate for the absence
of IL-3. 
Previous observations revealed that even though there is
minor to low cross-reactivity of human GM-CSF and SCF
between mouse and humans, overexpression in the NSGS
mice increased the number of mouse myeloid cells at the
expense of erythropoiesis.43 Normally cytokine genes are
expressed transiently and at low levels. Due to the use of
powerful promoters and multiple integrations of the trans-
gene, the quantity of cytokines secreted would be high in
transgenic organisms and might lead to increased stress in
the animals. Using a weak expression system will help
overcome this phenomenon. The effect of prolonged expo-
sure to human GM-CSF and SCF had not previously been
studied in zebrafish, providing another reason for our
choice of an inducible promoter. As observed when cells
from the ML-DS line (CMK) were transplanted into GSS
fish compared with casper controls, we observed enhanced
proliferation supported by the cytokine milieu (likely pre-
dominantly GM-CSF, to which CMK cells are known to be
responsive47) and a concomitant enhanced inhibition of pro-
liferation following treatment with cytarabine.
Our results from primary AML cells regarding latency
and mortality are consistent with findings from the NSGS
mouse model,11 but the zebrafish model offers the benefit
of medium- to high-throughput that can be applied in drug
screening with survival as a readout. Furthermore, using
ECS, we demonstrated that human AML transplanted into
GSS larvae maintain better clonal representation than trans-
plants into zebrafish lacking human cytokines. These find-
ings are indicative of the GSS fish providing a more clinical-
ly representative microenvironment to that found in
humans. 
Given the results observed with patient-derived AML
transplantation into GSS zebrafish, we hypothesized that
these humanized zebrafish might provide an improved
host environment for engrafting human blood stem cells,
which to date has been a challenge in the zebrafish field.24
As previously demonstrated, umbilical cord blood-derived
HSPC did not survive in control larvae but survived until 72
hpi in the GSS larvae, marking a substantive improvement
over the current limit of 13 hours reported in the literature.25
ECS performed from these two different transplant popula-
tions revealed the upregulation of human genes specific to
self-renewal only in the GSS larvae. The maintenance of
this key stem cell characteristic exclusively in the GSS lar-
vae affirms the utility of the “GSS human HSPC model” as
a platform for studying drugs that enhance stem cell expan-
sion in vivo. By contrast, we saw significant levels of all tran-
scripts associated with multilineage differentiation, except
for T-cell differentiation, in both control and GSS larvae.
While the myeloid bias in GSS fish might be expected due
to expression of GM-CSF and SCF,11,43 an absence of lym-
phoid cell differentiation in control larvae may be account-
ed for by the natural timeline of zebrafish lymphocyte
development (the thymus does not appear until 5 dpf) and
the lack of endogenous lymphoid-specific cytokines at this
experimental time point. With growing interest in and effi-
cacy of T-cell-mediated cancer immunotherapy and the
absence of a fully functional adaptive immune system in
zebrafish larvae until 1 month of age, this model is poised
for further manipulation with respect to T-cell differentia-
tion as a future platform for the preclinical testing of novel
immunotherapy approaches using human cancer and HSPC
co-transplantation. 
In summary, through the generation of novel humanized
zebrafish that express key hematopoietic cytokines, this
study exploits the previously recognized imaging and high-
er-throughput screening advantages of the zebrafish model
system to create a powerful new preclinical tool. The GSS
fish, in conjunction with ECS bar-coding, can be used to
screen for and also validate anti-leukemic and stem cell
expanding therapeutics and contribute to the goal of pro-
viding biologically rational personalized treatment to
patients.
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